Dolutegravir

Drug Profile

Dolutegravir

Alternative Names: '572; 1349572; Dolutegravir sodium; DTG; GSK-1349572; S-349572; S/GSK 1349572; Tivicay

Latest Information Update: 07 Jun 2017

Price : $50

At a glance

  • Originator Shionogi-GlaxoSmithKline Pharmaceuticals
  • Developer Bellvitge University Hospital; GlaxoSmithKline; INSERM; National Institute of Allergy and Infectious Diseases; Shionogi-GlaxoSmithKline Pharmaceuticals; University of Liverpool; ViiV Healthcare
  • Class 3-ring heterocyclic compounds; Amides; Antiretrovirals; Oxazines; Small molecules
  • Mechanism of Action HIV integrase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - HIV-1 infections
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed HIV-1 infections
  • Phase III HIV infections

Most Recent Events

  • 31 Mar 2017 ViiV Healthcare and GlaxoSmithKline plan a phase I trial for HIV-1 infections (In volunteers) (NCT03095638)
  • 14 Mar 2017 Phase-II/III clinical trials in HIV-1 infections (Combination therapy) in Uganda (PO) (NCT02245022)
  • 14 Mar 2017 University of Liverpool initiates a phase-II/III trial in HIV-1 infections (Combination therapy) in South Africa (NCT02245022)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top